

Please amend the paragraph beginning at line 20 of page 21 with the following rewritten paragraph:

--Additional examples of specific deletions comprise or essentially consist of residues 4 to 29, residues 7 to 29, and residues 10 to 29, respectively, of the fragment: Ala - Leu - Asp - Ala - Ala - Tyr - Cys - Phe - Arg - Asn - Val - Gln - Asp - Asn - Cys - Cys - Leu - Arg - Pro - Leu - Tyr - Ile - Asp - Phe - Lys - Arg - Asp - Leu - Gly (SEQ ID NO:1); i.e. fragments or compositions of fragments comprising either--

Please amend the paragraphs beginning at line 18 of page 29 and ending at line 8 of page 30 with the following rewritten paragraphs:

--In another interesting embodiment of the present invention the fragment of TGF- $\beta$  capable of eliciting an immunostimulating effect comprises the amino acid sequence:

X-A-Arg-B-Leu-Tyr-Ile-Asp-Phe-H-I-Asp-Leu-Gly-Trp-Lys (SEQ ID NO:3),

wherein X is Cys or a crosslinker moiety or a polypeptide that has at its C-terminus a Cys, and that, if greater than 15 residues, does not have the sequence of mature or precursor

TGF- $\beta$  at a homologous location in the mature or precursor TGF- $\beta$  molecule; and

wherein A is Val or Leu; B is Pro or Gln; H is Arg or Lys; and I is Lys, Arg, or Gln; or a physiologically acceptable salt or ester thereof; with the proviso that the TGF- $\beta$  fragment excludes (a) a full-length mature TGF- $\beta$  molecule or precursor TGF- $\beta$  molecule or deletion variants of mature or precursor TGF- $\beta$  molecules in which from about 1 to 10 amino acid residues have been deleted, (b) a fragment of the sequence: Cys-Val-Arg-Gln-Leu-Tyr-Ile-Asp-Phe-Arg-Lys-Asp-Leu-Gly-Trp-Lys (SEQ ID NO:4), and (c) a fragment of the sequence: Arg-Asn-Leu-Glu-Glu-Asn-Cys-Cys-Val-Arg-Pro-Leu-Tyr-Ile-Asp-Phe-Arg-Gln-Asp-Leu (SEQ ID NO:5).

Preferred fragments are Cys-Leu-Arg-Pro-Leu-Tyr-Ile-Asp-Phe-Lys-Arg-Asp-Leu-Gly-Trp-Lys (SEQ ID NO: 2); Cys-A-Arg-B-Leu-Tyr-Ile-Asp-Phe-H-I-Asp-Leu-Gly-Trp-Lys (SEQ ID NO:6), and Cys-Val-Arg-B-Leu-Tyr-Ile-Asp-Phe-Arg-I-Asp-Leu-Gly-Trp-Lys (SEQ ID NO:7), wherein: B is Pro or Gln; and/or I is Lys or Gln; and A and H are as defined herein above. It is more preferred that B is Gln and I is Lys, and that B is Pro and I is Gln.--

---

Please amend the paragraph beginning at line 32 of page 51 with the following rewritten paragraph:

b4 --In one embodiment of the present invention the immunogenic determinant is derived from a Parvovirus. Said immunogenic determinant could be naturally occurring or it could be synthesized in vitro. For example said immunogenic determinant could be a polypeptide, such as a polypeptide comprising the amino acid sequence CDGAVQPDGGQPAVRNER (SEQ ID NO:8) or a derivative thereof. Another example of a preferred immunogenic determinant is recombinant *A. salmonicida* outer membrane protein (rAsOMP). rAsOMP could for example be produced in *E. coli*. Preferably, rAsOMP is used at a final purity of ~75%.--

✓ Please amend the paragraph beginning at line 15 of page 59 with the following rewritten paragraph:

b5 --(Abbreviations: PBS = Phosphate Buffered Saline; crude fraction = composition comprising TGF-29 at a purity of about 50%; Parv: Synthesised 18-mer parvo virus peptide derivate acetyl-CDGAVQPDGGQPAVRNER-amide (SEQ ID NO:8), purity more or about 95% (R831, ID-LELYSTAD, The Netherlands, ref: Langeveld J.P.M., Casal J.I., Osterhaus A.D.M.E., Corter E., de Swart R., Vela C., Dalsgaard K., Puijk W.C., Schaaper W.M.M. and Meloen R.H. (1994). First peptide vaccine providing protection against viral infection in the target animal: Studies of canine parvovirus in dogs. J. Virology 68:4506-4513.))--

Please amend the paragraph beginning at line 31 of page 61 with the following rewritten paragraph:

--(Abbreviations: Tris-HCl : Tris is a common trade name for a commercially (eg.Sigma) available buffer salt solution adjusted with H<sub>2</sub>O and HCl to desired pH and molarity; purified TGF-29 = composition comprising TGF-29 at a purity of about 95%; Parv: Synthesised 18-mer parvo virus peptide derivate acetyl-CDGAVQPDGGQPAVRNER-amide (SEQ ID NO:8), purity more or about 95% (R831, ID-LELYSTAD, The Netherlands, ref: Langeveld J.P.M., Casal J.I., Osterhaus A.D.M.E., Corter E., de Swart R., Vela C., Dalsgaard K., Puijk W.C., Schaaper W.M.M. and Meloen R.H. (1994). First peptide vaccine providing protection against viral infection in the target animal: Studies of canine parvovirus in dogs. J. Virology 68:4506-4513)).--

Please amend the paragraph beginning at line 19 of page 66 with the following rewritten paragraph:

--(Abbreviations: Titermax adjuvant : Titermax Classical Adjuvant, Product no H4397, SIGMA-ALDRICH DENMARK A/S; Purified TGF-29 = composition comprising TGF-29 at a purity of about 95%; Parv: Synthesised 18-mer parvo virus peptide derivate acetyl-CDGAVQPDGGQPAVRNER-amide (SEQ ID NO:8), purity more or about 95% (R831, ID-LELYSTAD, The

B7  
Coral

Netherlands, ref: Langeveld J.P.M., Casal J.I., Osterhaus  
A.D.M.E., Corter E., de Swart R., Vela C., Dalsgaard K., Puijk  
W.C., Schaaper W.M.M. and Meloen R.H. (1994). First peptide  
vaccine providing protection against viral infection in the  
target animal: Studies of canine parvovirus in dogs. J.  
Virology 68: 4506-4513)).--

---

IN THE SEQUENCE LISTING

Please substitute the attached Sequence Listing,  
numbered as pages 1-4 for the Sequence Listing previously  
submitted as pages 56-57 and renumber the subsequent pages  
accordingly.